The potential shared role of inflammation in insulin resistance and schizophrenia: A bidirectional two-sample mendelian randomization study by Perry, Benjamin I. et al.
RESEARCH ARTICLE
The potential shared role of inflammation in




1,2*, Stephen BurgessID3, Hannah J. Jones4,5, Stan Zammit4,5,6,
Rachel Upthegrove7, Amy M. MasonID




9, Peter B. JonesID
1,2, Golam M. KhandakerID
1,2
1 Department of Psychiatry, University of Cambridge School of Clinical Medicine, Cambridge, England,
2 Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, England, 3 MRC Biostatistics Unit,
University of Cambridge, Cambridge, England, 4 NIHR Biomedical Research Centre, University Hospitals
Bristol NHS Foundation Trust and University of Bristol, Bristol, United Kingdom, 5 Centre for Academic
Mental Health, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, England,
6 MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, Wales, 7 Institute for
Mental Health, University of Birmingham, Birmingham, England, 8 Department of Public Health and Primary
Care, University of Cambridge, Cambridge, England, 9 MRC Epidemiology Unit, University of Cambridge




Insulin resistance predisposes to cardiometabolic disorders, which are commonly comorbid
with schizophrenia and are key contributors to the significant excess mortality in schizophre-
nia. Mechanisms for the comorbidity remain unclear, but observational studies have impli-
cated inflammation in both schizophrenia and cardiometabolic disorders separately. We
aimed to examine whether there is genetic evidence that insulin resistance and 7 related
cardiometabolic traits may be causally associated with schizophrenia, and whether evi-
dence supports inflammation as a common mechanism for cardiometabolic disorders and
schizophrenia.
Methods and findings
We used summary data from genome-wide association studies of mostly European adults
from large consortia (Meta-Analyses of Glucose and Insulin-related traits Consortium
(MAGIC) featuring up to 108,557 participants; Diabetes Genetics Replication And Meta-
analysis (DIAGRAM) featuring up to 435,387 participants; Global Lipids Genetics Consor-
tium (GLGC) featuring up to 173,082 participants; Genetic Investigation of Anthropometric
Traits (GIANT) featuring up to 339,224 participants; Psychiatric Genomics Consortium
(PGC) featuring up to 105,318 participants; and Cohorts for Heart and Aging Research in
Genomic Epidemiology (CHARGE) consortium featuring up to 204,402 participants). We
conducted two-sample uni- and multivariable mendelian randomization (MR) analysis to
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test whether (i) 10 cardiometabolic traits (fasting insulin, high-density lipoprotein and triglyc-
erides representing an insulin resistance phenotype, and 7 related cardiometabolic traits:
low-density lipoprotein, fasting plasma glucose, glycated haemoglobin, leptin, body mass
index, glucose tolerance, and type 2 diabetes) could be causally associated with schizo-
phrenia; and (ii) inflammation could be a shared mechanism for these phenotypes. We con-
ducted a detailed set of sensitivity analyses to test the assumptions for a valid MR analysis.
We did not find statistically significant evidence in support of a causal relationship between
cardiometabolic traits and schizophrenia, or vice versa. However, we report that a geneti-
cally predicted inflammation-related insulin resistance phenotype (raised fasting insulin
(raised fasting insulin (Wald ratio OR = 2.95, 95% C.I, 1.38–6.34, Holm-Bonferroni corrected
p-value (p) = 0.035) and lower high-density lipoprotein (Wald ratio OR = 0.55, 95% C.I.,
0.36–0.84; p = 0.035)) was associated with schizophrenia. Evidence for these associations
attenuated to the null in multivariable MR analyses after adjusting for C-reactive protein, an
archetypal inflammatory marker: (fasting insulin Wald ratio OR = 1.02, 95% C.I, 0.37–2.78,
p = 0.975), high-density lipoprotein (Wald ratio OR = 1.00, 95% C.I., 0.85–1.16; p = 0.849),
suggesting that the associations could be fully explained by inflammation. One potential limi-
tation of the study is that the full range of gene products from the genetic variants we used
as proxies for the exposures is unknown, and so we are unable to comment on potential bio-
logical mechanisms of association other than inflammation, which may also be relevant.
Conclusions
Our findings support a role for inflammation as a common cause for insulin resistance and
schizophrenia, which may at least partly explain why the traits commonly co-occur in clinical
practice. Inflammation and immune pathways may represent novel therapeutic targets for
the prevention or treatment of schizophrenia and comorbid insulin resistance. Future work is
needed to understand how inflammation may contribute to the risk of schizophrenia and
insulin resistance.
Author summary
Why was this study done?
• Cardiometabolic disorders such as diabetes are up to 30% more common in people with
schizophrenia than in the general population, and are among the predominant causes of
a 10- to 15-year shortened life expectancy in people with schizophrenia.
• Insulin resistance, a precursor to diabetes, is sometimes detectable in young adults suf-
fering their first episode of psychosis, which suggests that chronic lifestyle and clinical
factors, such as smoking, physical inactivity, and medication side effects may not fully
explain the comorbidity.
• Inflammation has been consistently associated with schizophrenia and cardiometabolic
disorders, and so could be a common mechanism for schizophrenia and cardiometa-
bolic disorders. This could help to at least in part explain why people who have
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1038/ng.3714). Full summary statistics for all traits
used in the primary analysis are freely and publicly
available for download at consortia/group websites.
Specifically; for fasting insulin, FPG, HbA1C and
glucose tolerance summary data, see https://www.
magicinvestigators.org/downloads/; For HDL, LDL
and triglycerides summary data, see http://csg.sph.
umich.edu/willer/public/lipids2013/; For BMI
summary data, see https://portals.broadinstitute.
org/collaboration/giant/index.php/GIANT_
consortium_data_file s; For T2DM, see https://
diagram-consortium.org/downloads.html; For
leptin summary data, see ftp://ftp.ebi.ac.uk/pub/
databases/gwas/summary_statistics/
KilpelainenTO_26833098_GCST0 03368; For
schizophrenia summary data, see https://www.
med.unc.edu/pgc/download-results/. Summary
GWAS data for CRP, which formed part of our
post-hoc sensitivity analysis, are also publicly
available from the primary GWAS study [35], and
inquiries regarding use of CRP summary data can
be sent to s.ligthart@erasmusmc.nl.
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schizophrenia also have higher rates of cardiometabolic disorders, over and above the
commonly attributed lifestyle/clinical factors.
What did the researchers do and find?
• To examine whether insulin resistance and 7 related cardiometabolic traits causally
influence schizophrenia risk or vice versa, we conducted bidirectional, two-sample, uni-
and multivariable mendelian randomizsation (MR) analyses. The MR approach uses
genetic variants as proxies for modifiable exposures to untangle the problems of reverse
causation and unmeasured confounding.
• To test a hypothesis that inflammation may be a common mechanism for schizophrenia
and cardiometabolic disorders, we also examined a subset of genetic variants which
were associated with inflammation as well as the cardiometabolic trait. We also used
multivariable MR (MVMR) as a sensitivity analysis to adjust for C-reactive protein
(CRP), an archetypal inflammatory marker, as a general downstream marker of sys-
temic inflammation.
• After correction for multiple testing, overall, there was no significant evidence in sup-
port of a causal relationship between cardiometabolic traits and schizophrenia, or vice
versa. However, we found evidence that supports a causal relationship of an inflamma-
tion-related insulin resistance phenotype with schizophrenia.
• Evidence for the association of an inflammation-related insulin resistance phenotype
with schizophrenia attenuated fully in MVMR analysis after adjusting for CRP, suggest-
ing that these associations may be underpinned by inflammation.
What do these findings mean?
• These results suggest that cardiometabolic traits are unlikely to have a causal role in the
pathogenesis of schizophrenia or vice versa. However, our results suggest that inflam-
mation is related to the risk of both schizophrenia and insulin resistance, which may at
least partly explain why they commonly occur in clinical practice.
• Treating or preventing inflammation may be a putative therapeutic option for preven-
tion and/or treatment of both schizophrenia and comorbid insulin resistance.
• In the future, more research is needed to understand the biological mechanisms under-
pinning how inflammation may increase the risk of schizophrenia and insulin
resistance.
Introduction
Schizophrenia is a complex behavioural and cognitive syndrome characterised primarily by
disruptions to perception and cognition [1]. It has a lifetime prevalence of around 0.4% [2] but
carries a significant global disease burden [3]. Cardiometabolic disorders are up to 30% more
common in schizophrenia than the general population [4] and are the leading contributors to
premature death in these patients [5]. Their increased prevalence in schizophrenia is
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commonly attributed to the adverse effects of antipsychotic medications [6] or lifestyle factors
such as physical inactivity and a poor diet [7], but this is unlikely to be the whole story. While
the aforementioned factors contribute cumulative risk over time [8], recent meta-analyses of
case–control studies suggest that a phenotype of raised fasting insulin, raised triglycerides, and
low high-density lipoprotein (HDL) cholesterol, indicative of insulin resistance [9–11], is asso-
ciated with relatively young antipsychotic-naïve patients with first-episode psychosis (FEP)
[12,13], and, cross-sectionally, with psychotic symptoms in young adults [14]. Therefore, insu-
lin resistance, which is a significant risk factor for type 2 diabetes mellitus (T2DM) and obesity,
might be causally related to, or share pathophysiologic mechanisms with schizophrenia.
The majority of existing research in the field is cross-sectional, and therefore cannot con-
firm whether cardiometabolic disorders are a cause or consequence of illness (i.e., reverse cau-
sality). For example, 1 longitudinal study found no evidence for an association between insulin
resistance in childhood and risk of psychosis in late adolescence [14]. Additionally, while pre-
vious studies have adjusted for a number of potential confounders, residual confounding,
which is a limitation of both cross-sectional and longitudinal research, could still be relevant.
Mendelian randomization (MR) analysis can address these limitations by using genetic vari-
ants inherited randomly at conception as unconfounded proxies of a modifiable exposure, to
examine whether the exposure may have a causal effect on a disease outcome [15]. MR studies
of cardiometabolic traits and schizophrenia are limited, have focused on a very limited set of
cardiometabolic exposures, and have reported mixed findings [16,17]. To our knowledge, MR
studies examining associations between a wide range of cardiometabolic traits and schizophre-
nia are lacking. Such studies may help to identify common potentially causal risk factors and
pathophysiologic mechanisms for these physical and psychiatric illnesses.
Inflammation could be pathophysiologically related to cardiometabolic disorders and
schizophrenia. Higher levels of circulating inflammatory markers have been associated with
both psychosis and cardiometabolic disorders, both cross-sectionally and longitudinally [18–
20]. MR studies have reported potential causal associations between inflammation, particularly
C-reactive protein (CRP) and interleukin-6 (IL-6), and schizophrenia [21,22]. CRP and IL-6
are also implicated in pathogenesis of insulin resistance [23] and may exaggerate the effects of
insulin resistance on psychosis risk in young adults [14]. However, to our knowledge, no MR
studies have examined whether inflammation could be pathophysiologically related to insulin
resistance and schizophrenia, for example, via mediating or common causal mechanisms.
Therefore, we have conducted a study to examine evidence in support of 4 scenarios regard-
ing the potential relationships between inflammation, insulin resistance, and schizophrenia:
(1) Inflammation is a common cause (confounder) between insulin resistance and schizophre-
nia; (2) insulin resistance mediates an association between inflammation and schizophrenia;
or vice versa; (3) inflammation is a common cause (confounder) between schizophrenia and
insulin resistance; and (4) schizophrenia mediates an association between inflammation and
insulin resistance. See S1 Methods for directed acyclic graphs (DAGs) illustrating the proposed
mechanisms.
First, we carried out MR analyses to test whether 10 cardiometabolic traits related to insulin
resistance (fasting insulin, triglycerides, HDL, low-density lipoprotein (LDL), fasting plasma
glucose (FPG), body mass index (BMI), glucose tolerance, leptin, glycated haemoglobin
(HbA1C), and T2DM) could be causally associated with schizophrenia. To test the direction of
association, we used genetically predicted levels of cardiometabolic traits as exposures and
schizophrenia as the outcome and vice versa. Next, we examined whether inflammation could
be a shared mechanism linking insulin resistance and schizophrenia using MR analyses
including genetic variants for each cardiometabolic trait that were also associated with a
marker of inflammation. Finally, we used multivariable MR (MVMR) analysis to control for
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genetic associations of cardiometabolic traits with CRP, an archetypal general inflammatory
marker, which we used as a general measure for systemic inflammation.
Methods
Selection of genetic variants related to cardiometabolic traits and
schizophrenia
For fasting insulin, triglycerides, and HDL, we used a set of 53 single nucleotide polymor-
phisms (SNPs) reported to be associated with all 3 traits, representative of an insulin resistance
phenotype, from a recent meta genome-wide association study (GWAS) of 188,577 European
adults, which adjusted for BMI [11]. In our study, we included SNPs reaching genome-wide
significance for the corresponding trait. Summary statistics for genome-wide significant SNPs
were also obtained for 6 related continuous (FPG, HbA1C, LDL, BMI, leptin, and glucose tol-
erance) and 1 binary (T2DM) cardiometabolic traits from recent large GWAS (S2–S10 Meth-
ods). We obtained summary statistics for schizophrenia from a recent GWAS from the
Psychiatric Genomics Consortium (PGC) [24] based on 40,675 cases and 64,643 European
controls. The degree of sample overlap between exposure and outcome samples was likely to
be low since exposure and outcome data were obtained from different consortia [25].
Ethics statement
Our study was a secondary analysis of the above publicly available data. Informed consent was
sought for all participants per the original GWAS protocols, and all ethical approvals for the
GWAS were obtained by original GWAS authors.
Statistical analysis
The analysis plan was prospectively conceived by the authors in 2019 but was not formally
deposited in a repository or database. All described analyses were planned a priori except for
the following: a) the analysis of inflammation-related SNPs at a less-stringent significance
threshold (see the ‘Analysis using inflammation-related SNPs’ section below); b) the MVMR
analysis including CRP (see the ‘Adjustment for Inflammation’ section below). These analyses
were conceived and conducted in light of findings from the primary analysis, to further probe
whether inflammation could explain the results. We obtained summary-level data (SNP rs
number, β-coefficient or log odds ratio (OR), standard errors or 95% confidence intervals
(CIs), effect allele, other allele, p-value, effect allele frequency, sample size, and number of
cases/controls) from each GWAS. Where a specific instrument SNP was not available in the
outcome dataset, we located proxy SNPs using linkage disequilibrium (LD) tagging (r2 > 0.8)
via LDlink [26]. Alleles were harmonised based on matching alleles, and the resulting instru-
ments were clumped for LD to ensure independence (10,000 kb pairs apart, r2 < 0.001). In the
event of palindromic SNPs, the forward strand was inferred where possible using allele fre-
quency information. We performed bidirectional analysis (i.e., with schizophrenia as exposure
and cardiometabolic traits as outcomes) to examine direction of association. Statistical analysis
was conducted using the TwoSampleMR package (v0.5.4) [27] for R (The R Foundation for
Statistical Computing, Vienna, Austria) [28]. Our primary MR analysis method was inverse
variance weighted (IVW) regression where at least two exposure SNPs were available for anal-
ysis. Where one exposure SNP was available for analysis, we used the Wald ratio method. We
also conducted weighted median and MR–Egger regression analysis (S11 Methods). For the
binary outcome of schizophrenia, the estimates for continuous exposures (fasting insulin,
HDL, triglycerides, LDL, FPG, BMI, HbA1C, glucose tolerance, and leptin) represent log-odds
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ratios converted into ORs, representing the increase in risk of schizophrenia per standard devi-
ation (SD) of exposure, and 95% CIs. For binary exposures (T2DM), the estimates represent
the OR for schizophrenia per unit increase in the log-odds of T2DM. For continuous cardio-
metabolic outcomes, β-coefficients represent the SD increase in exposure per unit increase in
the log-odds of schizophrenia, with standard errors (SEs).
We performed several sensitivity analyses to check the validity of our results. Heterogeneity
among SNPs included in each analysis was examined using the Cochran Q test. We checked
for horizontal pleiotropy using the MR–Egger regression intercept alongside a more recent
and robust method to detect horizontal pleiotropy and outliers, “MR pleiotropy residual sum
and outlier” (MR-PRESSO) [29]. Using MR-PRESSO, we used the global test to examine for
horizontal pleiotropy, and where evident, used the method to correct the IVW-estimate via
outlier removal (S11 Methods). We examined for measurement error in SNP-exposure associ-
ations using the I2GX statistic [30]. This study is reported as per the Strengthening the Report-
ing of MR studies (STROBE-MR) guideline [31] (S1 Checklist) and the Strengthening the
Reporting of Observational Studies in Epidemiology (STROBE) statement [32] (S2 Checklist).
Analysis using inflammation-related SNPs
Next, we repeated MR analysis using only inflammation-related SNPs for each cardiometabolic
risk factor as an instrumental variable for the outcome of schizophrenia. We did this to test the
hypothesis that these SNPs may represent a mechanism involving inflammation. This could be
via, for example, a common causal basis (panel A in S1 Methods) or via vertical (mediating)
pleiotropy [27] (panel B in S1 Methods). We used Phenoscanner v2 (University of Cambridge,
United Kingdom) [33] to examine each SNP associated with each cardiometabolic risk factor,
to identify SNPs that were also associated with a measure of inflammation, defined as blood
concentration/count of cytokines (such as chemokines, interferons, interleukins, lymphokines,
or tumour necrosis factors), acute phase proteins (e.g., CRP), or immune cells (e.g., neutrophils
and lymphocytes). Primarily, we considered inflammation-related SNPs at genome-wide signif-
icance (p<5×10-8) to maximise specificity. We also performed a sensitivity analysis by including
inflammation-related SNPs at a less-stringent nominal significance threshold (p<1x10-4) to
increase sensitivity to inflammation-related SNPs [34] (S12–S17 Methods).
Using the same method, we identified inflammation-related schizophrenia SNPs (S18
Methods) and used them as instrumental variables in MR analysis examining cardiometabolic
traits as outcomes.
Adjustment for inflammation
As a post hoc sensitivity analysis to estimate whether any associations evident above may be
explained by inflammation, we carried out MVMR analysis [34,35] using the 53 SNPs for fasting
insulin, triglycerides, and HDL, representative of an insulin resistance phenotype, as exposures
with schizophrenia as the outcome, after conditioning on the associations of these 53 SNPs with
CRP. We chose CRP because it is a widely used downstream measure of systemic inflammation,
and publicly available data from large-scale GWAS for CRP are available. Summary statistics for
CRP were obtained from a recent large GWAS based on 204,402 participants [36]. For CRP as an
exposure in MVMR, we used all independent (10,000 kb pairs apart, r2< 0.001) SNPs reported to
be conditionally associated with CRP and located within the CRP coding region (S19 Methods).
Correction for multiple testing
Statistical significance was estimated using the Holm–Bonferroni correction method [37], cor-
recting for the number of exposures tested at each stage of analysis.
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Results
MR analyses using all genetic variants associated with insulin resistance
and other cardiometabolic traits
We did not find significant evidence for associations between genetically-predicted levels of
cardiometabolic traits and schizophrenia, using the primary IVW analysis method. Evidence
using the weighted median method for associations between genetically-predicted levels of tri-
glycerides (weighted median OR = 1.26; 95% C.I., 1.06–1.50; corrected p = 0.090) and HDL
(weighted median OR = 0.79; 95% C.I., 0.65–0.95; corrected p = 0.126) with schizophrenia did
not survive correction for multiple testing (Table 1).
Table 1. MR analyses of cardiometabolic traits and schizophrenia using all SNPs.
Risk Factor SNPs,
No.a
Method Odds Ratio (95% C.I.) p-value Corrected p-valueb
Fasting Insulin 9 IVW 1.13 (0.76–1.70) 0.548 1.000
Weighted Median 0.98 (0.68–1.41) 0.920 1.000
MR Egger 9.24 (1.82–46.97) 0.028 0.280
Triglycerides 9 IVW 1.16 (0.86–1.56) 0.334 1.000
Weighted Median 1.26 (1.06–1.50) 0.009 0.090
MR Egger 1.31 (0.84–2.03) 0.308 1.000
HDL 14 IVW 0.94 (0.71–1.23) 0.649 1.000
Weighted Median 0.79 (0.65–0.95) 0.010 0.126
MR Egger 0.67 (0.45–0.99) 0.067 0.670
Fasting Plasma Glucose 18 IVW 1.07 (0.87–1.31) 0.522 1.000
Weighted Median 1.01 (0.84–1.23) 0.887 1.000
MR Egger 1.13 (0.74–1.74) 0.584 1.000
Type 2 Diabetes Mellitus 27 IVW 0.93 (0.78–1.12) 0.470 1.000
Weighted Median 0.93 (0.80–1.09) 0.375 1.000
MR Egger 1.03 (0.66–1.62) 0.895 1.000
Body Mass Index 81 IVW 1.05 (0.89–1.24) 0.554 1.000
Weighted Median 1.07 (0.92–1.24) 0.383 1.000
MR Egger 1.43 (0.97–2.10) 0.103 1.000
HbA1C 36 IVW 1.01 (0.76–1.32) 0.956 1.000
Weighted Median 1.12 (0.82–1.51) 0.483 1.000
MR Egger 1.33 (0.79–2.23) 0.295 1.000
Glucose Tolerance 7 IVW 0.98 (0.85–1.14) 0.800 1.000
Weighted Median 1.10 (0.87–1.15) 0.993 1.000
MR Egger 1.85 (0.95–3.32) 0.094 0.940
LDL 74 IVW 0.99 (0.93–1.05) 0.679 1.000
Weighted Median 0.97 (0.90–1.03) 0.322 1.000
MR Egger 0.98 (0.90–1.07) 0.692 1.000
Leptin 4 IVW 1.97 (0.90–4.31) 0.091 0.910
Weighted Median 1.18 (0.66–2.11) 0.579 1.000
MR Egger 3.29 (0.56–17.22) 0.358 1.000
HDL = high-density lipoprotein; HbA1C = glycated haemoglobin; LDL = low-density lipoprotein; IVW = inverse variance weighted regression; SNPs = single
nucleotide polymorphisms
aNumber of SNPs remaining after clumping for independence
b Each analysis method (IVW, Weighted Median and MR Egger) corrected using the Holm-Bonferroni method for 10 cardiometabolic markers
Estimates represent ORs for schizophrenia per SD increase in exposure (per unit-increase in log-odds of exposure for T2DM).
https://doi.org/10.1371/journal.pmed.1003455.t001
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MR analyses using inflammation-related genetic variants for insulin
resistance and other cardiometabolic traits
After testing only genome-wide significant inflammation-related SNPs for cardiometabolic traits,
we found evidence for associations of inflammation-related genetically-predicted fasting insulin
(Wald Ratio OR = 2.95; 95% C.I., 1.38–6.34; corrected p = 0.035) and HDL (Wald Ratio OR = 0.55;
95% CI, 0.36–0.84; corrected p = 0.035) with schizophrenia. We could not include any genome-
wide significant inflammation-related variants for triglycerides, leptin or glucose tolerance. In our
sensitivity analysis featuring inflammation-related cardiometabolic variants at a less stringent signif-
icance threshold, evidence persisted for associations of inflammation-related genetically-predicted
fasting insulin (IVW OR = 1.74; 95% C.I., 1.08–2.98; corrected p = 0.030) and HDL (IVW
OR = 0.78; 95% C.I., 0.62–0.92; corrected p = 0.036) with schizophrenia. In addition, we found evi-
dence for an association of genetically-predicted inflammation-related triglycerides (IVW
OR = 1.24; 95% C.I., 1.07–1.55; corrected p = 0.036) with schizophrenia (Table 2; Fig 1 & Fig 2).
Adjustment for inflammation
MVMR analysis for inflammation-related SNPs of fasting insulin, triglycerides, and HDL with
schizophrenia showed that the univariable associations fully attenuated after controlling for
the genetic associations of these variants with CRP, in analyses involving both inflammation-
related SNPs at genome-wide and nominal significance levels. Controlling for CRP had negli-
gible effect on MR estimates based on all genetic variants (Fig 3, S1 and S2 Results).
Test for bidirectionality using schizophrenia as exposure
We did not find statistically significant MR associations between schizophrenia and any cardi-
ometabolic trait after correction for multiple testing (S3 Results, S1 Fig). Similarly, we did not
find statistically significant MR associations of inflammation-related schizophrenia variants
with cardiometabolic traits after correction for multiple testing (S4 Results, S1 Fig).
Test for horizontal pleiotropy
Using the MR-Egger regression intercept test, we found evidence of potential horizontal plei-
otropy for BMI and HDL in the all-SNP analysis, but no evidence for horizontal pleiotropy for
any cardiometabolic exposure in the inflammation-related SNP analysis. Using MR-PRESSO
however, we found evidence that horizontal pleiotropy was likely to have affected estimates for
all cardiometabolic exposures in the all-SNP analysis (p value for global test all�0.020), and
both LDL and T2DM in the inflammation-related SNP analysis. Following MR-PRESSO out-
lier correction, evidence strengthened for the association of triglycerides with schizophrenia in
the all-SNP analysis (MR-PRESSO IVW β = 0.23, S.E. 0.06, p = 0.008), but outlier-corrected
IVW estimates for other exposures were not significantly altered.
In the bidirectional analyses, both MR-PRESSO and the MR-Egger regression intercept sug-
gested horizontal pleiotropy affecting the outcomes of HDL, BMI and LDL (all p<0.05). Follow-
ing outlier correction, there was evidence for a weak protective effect of schizophrenia on BMI
(β = -0.04, S.E. 0.02, p = 0.014). MR-PRESSO additionally revealed possible horizontal pleiotropy
affecting the outcomes of fasting insulin, triglycerides and T2DM (p for MR-PRESSO global test
all<0.05) (S5–S12 Results), but outlier-corrected IVW estimates were not significantly altered.
Test for heterogeneity of instruments
In the analyses based on all SNPs, the majority of cardiometabolic traits demonstrated evi-
dence of heterogeneity, which was reduced in the inflammation-related SNP analysis (S5–S8
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Results). There was limited evidence of heterogeneity in the sensitivity analyses based on
inflammation-related SNPs for T2DM, BMI, and HbA1C only.
Test for measurement error
Results for the I2GX tests for SNP-exposure associations revealed some evidence for potential
measurement error, which may have biased MR–Egger analyses in the analyses with leptin,
glucose tolerance, T2DM, and schizophrenia as exposures (S13 Results).
Table 2. MR analyses of inflammatory-related cardiometabolic SNPs and schizophrenia.
Risk Factor Method Genome-Wide Significant Inflammatory-Related
SNPs





p-value Corrected p-valuea SNPs,
No.
Odds Ratio (95% C.I.) p-value Corrected p-valuea
Fasting Insulin IVW / Wald
Ratio
1 2.95 (1.38–6.34) 0.005 0.035 5 1.74 (1.08–2.98) 0.003 0.030
Weighted Median 1.40 (0.83–2.34) 0.203 1.000
MR Egger 7.20 (1.03–50.54) 0.141 0.987
Triglycerides IVW / Wald
Ratio
0 � � � 4 1.24 (1.07–1.55) 0.004 0.036
Weighted Median 1.26 (1.06–1.50) 0.009 0.063
MR Egger 1.29 (1.02–1.63) 0.167 0.987
HDL IVW / Wald
Ratio
1 0.55 (0.36–0.84) 0.005 0.035 7 0.78 (0.62–0.92) 0.004 0.036
Weighted Median 0.77 (0.64–0.94) 0.008 0.056
MR Egger 0.68 (0.51–0.91) 0.047 0.288
Fasting Plasma Glucose IVW 2 1.53 (0.39–5.97) 0.537 1.000 4 1.04 (0.36–2.98) 0.945 1.000
Weighted Median 1.08 (0.63–1.86) 0.776 1.000
MR Egger 8.44 (0.65–120.54) 0.409 1.000
Type 2 Diabetes
Mellitus
IVW 7 0.94 (0.59–1.48) 0.776 1.000 10 0.97 (0.71–1.33) 0.850 1.000
Weighted Median 1.05 (0.26–4.32) 0.941 1.000 1.05 (0.74–1.48) 0.781 1.000
MR Egger 1.40 (0.32–6.08) 0.668 1.000 1.42 (0.59–3.38) 0.458 1.000
HbA1C IVW 7 1.20 (0.67–2.13) 0.546 1.000 10 1.02 (0.64–1.61) 0.942 1.000
Weighted Median 0.93 (0.46–1.85) 0.832 1.000 0.95 (0.54–1.69) 0.865 1.000
MR Egger 1.68 (0.39–7.21) 0.508 1.000 1.18 (0.41–3.37) 0.767 1.000
Body Mass Index IVW 4 1.23 (0.88–1.71) 0.229 1.000 12 1.48 (0.76–2.87) 0.249 1.000
Weighted Median 1.15 (0.80–1.65) 0.451 1.000 1.16 (0.85–1.58) 0.350 1.000
MR Egger 0.77 (0.33–1.79) 0.650 1.000 3.36 (0.61–18.45) 0.399 1.000
LDL IVW 13 0.96 (0.79–1.17) 0.687 1.000 23 0.93 (0.79–1.10) 0.420 1.000
Weighted Median 0.91 (0.80–1.04) 0.181 1.000 0.91 (0.80–1.04) 0.129 0.987
MR Egger 0.81 (0.58–1.14) 0.254 1.000 0.82 (0.62–1.11) 0.220 0.987
Leptin IVW 0 � � � 2 1.56 (0.77–3.17) 0.221 0.987
Glucose Tolerance IVW 0 � � � 2 1.06 (0.82–1.56) 0.882 1.000
HDL = high-density lipoprotein; HbA1C = glycated haemoglobin; LDL = low-density lipoprotein; IVW = inverse variance weighted regression; SNPs = single
nucleotide polymorphisms
aEach analysis method (IVW, Weighted Median and MR Egger) corrected using the Holm-Bonferroni method
�no inflammatory-related SNPs includedEstimates represent ORs for schizophrenia per SD increase in exposure (or per unit-increase in log-odds of binary exposures
e.g. T2DM).
https://doi.org/10.1371/journal.pmed.1003455.t002
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Fig 1. MR Analyses Testing Associations between Insulin Resistance Phenotypes (Fasting Insulin (A), Triglycerides (B) and HDL (C)) and Schizophrenia,
Highlighting Inflammation-Related SNPs. Points in plots represent the association of the genome-wide significant insulin-resistance single nucleotide
polymorphisms (SNPs) and their association with schizophrenia (Y axis) and the exposure (X axis). SNPs are denoted by green points in the plot. Inflammation-
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Discussion
Main findings
We conducted bidirectional uni- and multivariable two-sample MR analyses using large pub-
licly available genomic datasets to first examine for associations that support a causal relation-
ship between insulin resistance and related cardiometabolic traits and schizophrenia, and
second, to examine whether there is evidence to support that inflammation may be a common
causal mechanism for insulin resistance and schizophrenia. Using our primary IVW analysis
method, we did not find evidence in support of a causal association between genetically-pre-
dicted cardiometabolic traits and schizophrenia. However, we found weak evidence using the
weighted median method in support of a causal association of genetically-predicted levels of
triglycerides and HDL with schizophrenia, but this association did not survive correction for
multiple testing and the estimate may have been affected by horizontal pleiotropy. We found
more consistent evidence for an association of the insulin resistance phenotype of fasting insu-
lin, triglycerides, and HDL [11] with schizophrenia when we examined only genetic variants
also associated with inflammation. Using two p-value cut-offs for inflammation-related SNPs,
we found that the strength of association with schizophrenia increased as the specificity toward
inflammation-related SNPs increased. In MVMR analyses adjusting for CRP, those estimates
attenuated fully to the null. We found no evidence in bidirectional analyses in support of a
causal relationship of schizophrenia with insulin resistance (panels C and D in S1 Methods).
Together, our results are therefore most consistent with inflammation as a common cause for
insulin resistance and schizophrenia (panel A in S1 Methods).
Inflammation as a common cause for schizophrenia and insulin resistance
Three aspects of our results point towards inflammation as a common cause for insulin resis-
tance and schizophrenia (panel A in S1 Methods). First, we did not find convincing overall evi-
dence for a causal relationship between insulin resistance and schizophrenia (likely ruling out
panel B in S1 Methods). Second, in our analyses of inflammation-related variants for the cardi-
ometabolic traits, we found strong and consistent evidence in support of a potential causal
relationship of fasting insulin, HDL and triglycerides with schizophrenia, and the strength of
association with schizophrenia increased as the specificity toward inflammation-related SNPs
increased. Third, we used MVMR to evidence that after controlling for CRP, an archetypal
general inflammatory marker, the associations between inflammation-related genetic variants
for insulin resistance and schizophrenia completely attenuated. This result suggests that the
observed associations for the inflammation-related variants are at least in part explained by
inflammation. Together, the results are consistent with the idea that inflammation may be a
common causal mechanism for insulin resistance and schizophrenia.
Evidence for a common causal mechanism between insulin resistance and schizophrenia
may help to explain why schizophrenia is associated with higher rates of insulin resistance
even in early stages of illness, when the cumulative effects of medication and lifestyle factors
are relatively small [12,38]. Anti-inflammatory agents, of which several have shown promise in
treating the symptoms of schizophrenia [39], should therefore be considered as a putative ther-
apeutic target for prevention and treatment of cardiometabolic disorders in schizophrenia.
related SNPs at genome-wide significance are denoted by a purple border. Inflammation-related SNPs at nominal significance are denoted by a red border.
Whiskers represent standard errors. Lines on the plot represent inverse-variance weighted (>1 SNP) or linear regression (1 SNP) of all-SNPs (green line),
inflammation-related SNPs at genome-wide significance (purple line) and inflammation-related SNPs at nominal significance (red line).
https://doi.org/10.1371/journal.pmed.1003455.g001
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Fig 2. MR analyses testing associations between cardiometabolic traits and schizophrenia. Forest plot presents ORs and 95% CIs for associations between
cardiometabolic traits and schizophrenia using IVW / Wald Ratio MR analyses based on all single nucleotide polymorphisms (SNPs) associated with each risk factor
(green), inflammation-related SNPs at genome-wide significance (purple), and inflammation-related SNPs at nominal significance (red). See Tables 1 and 2 for the
number of SNPs used in each analysis. HDL = High Density Lipoprotein; T2DM = Type 2 Diabetes Mellitus; BMI = Body Mass Index; FPG = Fasting Plasma Glucose;
LDL = Low-Density Lipoprotein; HbA1C = Glycated Haemoglobin; Glucose Tol = Glucose Tolerance.
https://doi.org/10.1371/journal.pmed.1003455.g002
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Fig 3. Multivariable MR analysis testing associations between insulin resistance phenotypes and schizophrenia after controlling for genetic associations for CRP.
Forest plot presents ORs and 95% CIs for inverse-variance weighted regression (IVW) MR associations between insulin resistance phenotypes and schizophrenia using all
single nucleotide polymorphisms (SNPs) (dark green), and after controlling for association of these SNPs with C-reactive protein (CRP) using multivariable MR (MVMR)
(light green). The forest plot also presents ORs and 95% CIs for IVW / Wald Ratio MR associations between insulin resistance phenotypes and schizophrenia using
inflammation-related SNPs (genome-wide significance = dark purple; nominal significance = red), and after controlling for association of these SNPs with CRP using
MVMR (genome-wide significance = light purple; nominal significance = light red). HDL = high-density lipoprotein.
https://doi.org/10.1371/journal.pmed.1003455.g003
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We used CRP, an archetypal downstream inflammatory marker, as a means of gauging the
effect of systemic inflammation in MVMR analysis, rather than hypothesising a specific role
for CRP in the relationship between insulin resistance and schizophrenia. Nevertheless, CRP
has observationally shown in both cross-sectional [40] and longitudinal [41] research to be
associated with schizophrenia, although such findings are limited by the potential of residual
confounding and reverse causality. Interestingly, however, MR findings have reported that
genetically predicted CRP may have a protective effect on schizophrenia [21], with authors
positing that a genetically attenuated ability to produce CRP may predispose to more insidious
and chronic infections. In our MVMR analysis, attenuation of insulin resistance schizophrenia
associations after controlling for CRP is consistent with inflammation being associated with
both exposure and outcome, albeit “negatively” with the latter. Further research is needed to
explore potential mechanisms of association between CRP and schizophrenia.
Many of the SNPs included in the inflammation-related analysis were associated with neutro-
phils and/or lymphocytes. A raised neutrophil to lymphocyte ratio (NLR) is a marker of systemic
inflammation and is known to be associated with schizophrenia [42] and insulin resistance [43].
We were unable to find large GWAS studies conducted in European populations for NLR or for
other inflammatory markers, which we might have used in MVMR analyses in place of CRP.
Based on our findings, we are unable to completely rule out the possibility that insulin resis-
tance may mediate an inflammation–schizophrenia association (panel B in S1 Methods), since
there was weak evidence that did not survive correction for multiple testing for an association
of triglycerides and HDL with schizophrenia using the weighted median method, and in our
MR-PRESSO sensitivity analysis, evidence from the outlier-corrected IVW analysis suggested
a possible association between triglycerides and schizophrenia. These findings are broadly sim-
ilar to 1 previous MR study [17], which reported only weak evidence of an association between
the homeostasis model assessment (HOMA), a measure of insulin resistance, on schizophre-
nia. Another MR study [16] reported a genetic association between fasting insulin and schizo-
phrenia, although the evidence attenuated after adjustment for BMI. To account for BMI, we
obtained summary statistics for genetic variants related to insulin resistance after controlling
for BMI [11]. The previous MR study included an ethnically heterogeneous sample, increasing
the potential for population stratification bias. We used genetic data from a more ethnically
homogenous GWAS of schizophrenia [24]. Nevertheless, while our results in the all-SNP anal-
ysis suggested weak evidence for triglycerides and HDL, which may reflect an insulin resis-
tance phenotype, the evidence did not survive correction for multiple testing and requires
replication in future when larger GWAS samples are available.
The implications of our findings with regard to shared causal mechanisms should not distract
clinicians from focusing on the assessment and management of malleable lifestyle factors related
to cardiometabolic disorders in people with schizophrenia. Factors such as poorer diet, reduced
exercise and smoking, which are associated with schizophrenia [7,44,45], may predispose to an
inflammatory state [46]. Therefore, it is possible that lifestyle factors exacerbate a feedback loop
between inflammation, insulin resistance, and schizophrenia by increasing both inflammation
and insulin resistance, eventually leading to T2DM and other cardiometabolic disorders such as
obesity and cardiovascular disease (CVD). In addition to the potential therapeutic potential of
anti-inflammatory medications, malleable lifestyle factors must continue to remain crucial targets
[47,48] for the prevention of cardiometabolic morbidity in people with schizophrenia.
Additional findings
We report that after outlier correction, schizophrenia had a weak protective effect on BMI.
This finding complements estimates from previous research [53] using LD score regression,
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though we are able to advance previous findings since genetic correlation analyses are unable
to test direction of association. This finding suggests that weight gain associated with schizo-
phrenia is unlikely to be a feature of the illness itself but could be attributed to iatrogenic or
lifestyle effects. Moreover, the “lean insulin-resistance” phenotype may be associated with
higher levels of inflammation [54] and warrants further research in the context of schizophre-
nia, particularly since in younger patients, the “lean” nature of the phenotype may mean that
important cardiometabolic investigations may be overlooked in the clinic.
Strengths and limitations
Strengths of this study include the use of a large set of cardiometabolic traits and large GWAS
datasets, through which we were able to test specific biological mechanisms. We chose SNPs
reaching genome-wide significance from large GWAS and meta-GWAS for insulin resistance
and related cardiometabolic traits. We performed a comprehensive set of sensitivity analyses
to check MR assumptions. Furthermore, while weak instrument bias may be a factor in MR
analysis, in two-sample MR, this bias tends towards the null [55], thus would not explain the
positive associations we describe. We corrected for multiple testing to minimise potential type
I error.
Our study has some limitations. We did not select SNPs in known coding regions for the
exposures, for example, the IRS-1 gene for insulin resistance [56]. We took this step on the
assumption that many mechanisms at play may not yet be fully understood. For example,
while the heritability of cardiometabolic traits such as obesity is as high as 70%, the variance
currently explained by known genetic variants is but a small fraction of this [57]. In addition,
selecting SNPs from many different GWAS studies featuring large sample sizes may increase
the risk of sample overlap between exposure and outcome variables and can bias the results in
either direction, depending on the proportion of overlap [27]. Also, for our primary inflamma-
tion-related SNP analysis, we chose a stringent p-value threshold to define inflammation-
related SNPs. In doing so, we may have overlooked some SNPs with true inflammatory associ-
ations. As a result, only one genome-wide significant inflammation-related genetic variant was
included in the analysis of fasting insulin and HDL, and none were included for triglycerides.
Therefore, these results be considered with caution. However, we attempted to address this
limitation by relaxing the p-value threshold for inflammation-related SNPs, thereby allowing a
greater number of SNPs to be included, and the results for fasting insulin, HDL and triglycer-
ides were consistent. Yet, the inclusion of inflammation-related genetic variants at a relaxed
significance threshold may have increased the risk of weak instrument bias for those analyses.
In the future, larger and better-powered GWAS may identify more SNPs for analysis and at
greater resolution, potentially unearthing a larger number of inflammation-related SNPs,
which would be helpful to confirm our findings. Additionally, the full range of gene products
from the genetic variants we used as proxies for the cardiometabolic traits is unknown, and so
we are unable to comment on potential biological mechanisms of association other than
inflammation, which may also be relevant. Finally, our analyses were based on data from
mostly European participants, so it is unclear whether our results apply to other populations.
Large-scale GWAS and replication of our analyses in other populations are required to answer
this question.
Conclusions
It is well established that certain antipsychotic drugs and lifestyle factors such as smoking, lack
of exercise, and poor diet are important contributors to cardiometabolic comorbidity in people
with schizophrenia. In addition to this, our findings suggest that inflammation may be a
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common cause for schizophrenia and cardiometabolic disorders, which may at least partly
explain why they so commonly co-occur in clinical practice. Lifestyle modification and careful
prescription of certain antipsychotic medications remain crucial malleable targets to reduce
the significant impact that comorbid cardiometabolic disorders place on the quality and length
of life in people with schizophrenia. In addition, our findings suggest that targeting inflamma-
tion could be an important therapeutic target for the treatment and prevention of cardiometa-
bolic disorders in people with schizophrenia. Future research should seek to examine the
biological mechanisms, which underpin how inflammation can simultaneously increase the
risk of both insulin resistance and schizophrenia.
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